- Conditions
- Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
- Interventions
- Temozolomide, Stereotactic Radiosurgery (SRS)
- Drug · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 350
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, GBM, Brain Cancer
- Interventions
- VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine, Physician's Choice of Salvage Therapy - carboplatin
- Drug
- Lead sponsor
- DelMar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
- Conditions
- Melanoma (Skin)
- Interventions
- sorafenib tosylate, temozolomide
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma, CNS Disease, Brain Diseases
- Interventions
- Dasatinib, RT (Radiotherapy), TMZ (Temozolomide)
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- Stenoparib/Temozolomide, Lurbinectedin
- Combination Product · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Chicago, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Acute Myeloid Leukemia With 11q23-abnormality in Relapse
- Interventions
- Temozolomide, Vorinostat
- Drug
- Lead sponsor
- Steven E. Coutre
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
- Interventions
- Capecitabine, Temozolomide
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 446
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
- Conditions
- Melanoma
- Interventions
- Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide)
- Drug
- Lead sponsor
- Genta Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- Pembrolizumab, Olaparib, Temozolomide
- Drug
- Lead sponsor
- L. Nicolas Gonzalez Castro, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Brain Neoplasms
- Interventions
- Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
- Drug · Radiation · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
- Conditions
- Neuroendocrine Tumor
- Interventions
- Thalidomide, Temodar
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Solid Tumor
- Interventions
- Bevacizumab, Temozolomide, Vincristine, Irinotecan, Cefixime
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
- Interventions
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride, Temozolomide
- Other · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more
- Conditions
- Brain Cancer
- Interventions
- Temozolomide, Bevacizumab, Lithium Carbonate, Radiation
- Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Summit, New Jersey • New York, New York
- Conditions
- Neuroendocrine Tumors
- Interventions
- Capecitabine, Temozolomide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Central Nervous System Tumor, Pediatric
- Interventions
- filgrastim, cisplatin, cyclophosphamide, cytarabine, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, temozolomide, therapeutic hydrocortisone, vincristine sulfate, radiation therapy, Dactinomycin
- Biological · Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 12
- States / cities
- Stanford, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
- Interventions
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
- Radiation · Other · Biological + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration, Selinexor, Temozolomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 28 more
- Conditions
- Adult Brain Glioblastoma
- Interventions
- Treatment, Methoxyamine, Temozolomide
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Malignant Melanoma
- Interventions
- Temozolomide and SU11248
- Drug
- Lead sponsor
- Northern California Melanoma Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Neuroblastoma
- Interventions
- Humanized anti-GD2 antibody, Chemotherapy, Cytokines, Natural killer cells, CliniMACS
- Biological · Drug · Other + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
- Interventions
- enzyme-inducing anti-epileptic drugs
- Drug
- Lead sponsor
- Annick Desjardins
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- arsenic trioxide, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Naperville, Illinois